miRNA-642a-3p保护β细胞免受葡萄糖脂毒性影响
Sandra Sofia Pinhanços1,2,3,4, João Teixeira de Oliveira5,6, C Henrique Alves7,8,9,3
1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, 3060-197 Coimbra, Portugal.
Molecular therapy. Nucleic acids
|June 23, 2025
概括
研究人员确定了miR-642a-3p,这是一个保护胰腺β细胞免受葡萄糖脂毒性 (GLT) 诱导的细胞死亡的微RNA. 这一发现为治疗糖尿病和肥胖症提供了潜在的新工具.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 2型糖尿病 (T2DM) 的发病率与肥胖相关.
- 葡萄糖脂毒性 (GLT),高葡萄糖和脂肪酸,损害β细胞功能和生存.
- 识别针对GLT的保护机制对于T2DM管理至关重要.
研究的目的:
- 查微RNAs (miRNAs),保护胰腺β细胞免受GLT诱导的细胞死亡 (GICD).
- 为了研究一个特定的miRNA,miR-642a-3p在β细胞保护和功能中的作用.
主要方法:
- 在暴露于GLT的β细胞中选了2,080个人类miRNA模仿的库.
- 利用RNA测序来分析miR-642a-3p.p.诱导的基因表达变化.
- 从肥胖和T2DM患者的人类小岛和细胞外囊泡中评估胰岛素分泌和miRNA表达.
主要成果:
- 确定了45个保护β细胞免受GICD的miRNA;选择了miR-642a-3p进行进一步研究.
- miR-642a-3p恢复了β细胞身份基因,调节了细胞存活率和脂质代谢途径.
- miR-642a-3p保护β细胞免受GLT诱导的胰岛素分泌功能障碍.
- 在T2DM患者群岛中,miR-642a-3p的下调;在肥胖患者中,它的保护作用发生了变化.
结论:
- miR-642a-3p显示出作为T2DM和肥胖的生物标志物的潜力.
- miR-642a-3p作为β细胞生存和功能的促进剂.
- 这种miRNA代表了糖尿病和肥胖管理的新型治疗目标.
相关概念视频
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


